• Publications
  • Influence
Crocus sativus L. in the treatment of mild to moderate depression: a double‐blind, randomized and placebo‐controlled trial
Depression is a serious disorder in today's society, with estimates of lifetime prevalence as high as 21% of the general population in some developed countries. As a therapeutic plant, saffron isExpand
  • 251
  • 13
  • PDF
Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomized and placebo‐controlled trial
Background:  Alzheimer's disease is characterized by a slow, progressive decline in cognitive function and behaviour. Acetylcholine esterase inhibitors are the only agents approved by the Food andExpand
  • 278
  • 12
  • PDF
Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study.
BACKGROUND It has been proposed that the mechanism of the antidepressant effect of celecoxib is linked to its anti-inflammatory action and particularly its inhibitory effect on pro-inflammatoryExpand
  • 211
  • 11
Comparing Effects of Ketamine and Thiopental Administration During Electroconvulsive Therapy in Patients With Major Depressive Disorder: A Randomized, Double-Blind Study
Objectives Recently, ketamine has attracted attention for induction of anesthesia during electroconvulsive therapy (ECT). This study compared the effects of thiopental and ketamine in patientsExpand
  • 71
  • 11
Prevalence of obsessive-compulsive disorder in Iran
BackgroundEstimates of the annual prevalence for Obsessive Compulsive Disorder (OCD) were consistent across the international sites range, 1.9% – 2.5%. The nine population surveys, which usedExpand
  • 99
  • 11
Crocus sativus L. (petal) in the treatment of mild-to-moderate depression: a double-blind, randomized and placebo-controlled trial.
Depression is a major worldwide health problem. Indeed, by 2020, depressive disorders are estimated to represent the second largest disease burden worldwide. Although a variety of pharmaceuticalExpand
  • 189
  • 10
Adjunctive estrogen treatment in women with chronic schizophrenia: a double-blind, randomized, and placebo-controlled trial
The estrogen hypothesis of schizophrenia postulates that estrogen exerts a protective effect against schizophrenia and that this partly explains the observed sex differences in premorbid adjustment,Expand
  • 122
  • 10
Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial
Background: The pathophysiology of depression is associated with the hyperactivity of immune inflammatory responses. Cyclooxygenase‐2 inhibitors such as celecoxib reduce the production ofExpand
  • 287
  • 9
Celecoxib as adjunctive therapy in schizophrenia: A double-blind, randomized and placebo-controlled trial
Some evidence suggests that the pathophysiology of schizophrenia is associated with the abnormal immune system, and cytokines may be important in schizophrenia. Cyclooxygenase-2 (COX-2) inhibitorsExpand
  • 258
  • 9
Zinc sulfate as an adjunct to methylphenidate for the treatment of attention deficit hyperactivity disorder in children: A double blind and randomized trial [ISRCTN64132371]
BackgroundAttention-deficit hyperactivity disorder is an early-onset, clinically heterogenous disorder of inattention, hyperactivity, and impulsiveness. The diagnosis and treatment ofExpand
  • 168
  • 9
  • PDF